Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Fulcrum Therapeutics (FULC) EBIT Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed EBIT Margin for 5 consecutive years, with 65.61% as the latest value for Q2 2024.

  • Quarterly EBIT Margin rose 316698.0% to 65.61% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 15.58% through Mar 2025, up 446880.0% year-over-year, with the annual reading at 27.37% for FY2024, 391787.0% up from the prior year.
  • EBIT Margin for Q2 2024 was 65.61% at Fulcrum Therapeutics, up from 3213.78% in the prior quarter.
  • The five-year high for EBIT Margin was 65.61% in Q2 2024, with the low at 9471.19% in Q1 2023.
  • Average EBIT Margin over 5 years is 2044.08%, with a median of 1033.77% recorded in 2020.
  • The sharpest move saw EBIT Margin crashed -846818bps in 2023, then skyrocketed 316698bps in 2024.
  • Over 5 years, EBIT Margin stood at 420.99% in 2020, then decreased by -11bps to 465.78% in 2021, then crashed by -777bps to 4083.65% in 2022, then grew by 21bps to 3213.78% in 2023, then surged by 102bps to 65.61% in 2024.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 65.61%, 3213.78%, and 3615.28% for Q2 2024, Q4 2023, and Q3 2023 respectively.